Results 1 to 10 of about 1,207,383 (287)
Liver-directed therapies for colorectal liver metastases. [PDF]
CancerAbstract Colorectal cancer is the third most common cancer diagnosed in the United States, with an anticipated 53,000 deaths from this disease in 2025. Greater than one in five patients will present with synchronous colorectal liver metastases (CRLMs), and 25%–30% will develop CRLMs during the course of the disease.
Folkerts AD, Janczewski LM, Merkow RP.
europepmc +3 more sources
Colorectal liver metastases [PDF]
British Medical Bulletin, 2011 Despite major advances in therapies for liver metastases, colorectal cancer remains one of the commonest causes of cancer-related deaths in the UK.The international literature on the management of colorectal liver metastases (CLM) was reviewed.Due to a combination of highly active systemic agents and low perioperative mortality achieved by high-volume ...
Robert P, Sutcliffe +1 more
+8 more sources
PLoS ONE, 2023 BackgroundLiver metastases severely reduce the long term survival of colorectal cancer patients. Long non-coding RNAs (lncRNAs) CCAT1 and CCAT2 have previously been found to be associated with impaired patient outcomes in primary colorectal cancer.
Clemens Franz +5 more
doaj +3 more sources
Radioembolization for colorectal liver metastases [PDF]
Nature Reviews Clinical Oncology, 2010 Maurice A A J van den Bosch +2 more
exaly +3 more sources
Colorectal Liver Metastases [PDF]
Journal of Gastrointestinal Surgery, 2013 With modern multimodality therapy, patients with resected colorectal cancer (CRC) liver metastases (CLM) can experience up to 50-60 % 5-year survival. These improved outcomes have become more commonplace via achievements in multidisciplinary care, improved definition of resectability, and advances in technical skill.Even patients with synchronous and ...
Ching-Wei D, Tzeng, Thomas A, Aloia
openaire +2 more sources
Colorectal liver metastases [PDF]
Postgraduate Medical Journal, 1996 Summary Each year in the UK, between 12-14,000 people develop liver metastases from colorectal cancer. These metastases will contribute to the death of the patient in about 80% of cases. Treatments aimed at these tumours are best administered when the tumour is small.
D, Burke, T G, Allen-Mersh
openaire +2 more sources
Ablation therapy for patients with colorectal liver metastases with and without extrahepatic metastases: evaluation of long-term outcomes and prognostic factors [PDF]
Ultrasonography, 2023 Purpose Ablation is a valuable treatment alternative to surgery for colorectal liver metastases. This study reports the long-term clinical outcomes in patients treated with ablation for colorectal liver metastases with or without extrahepatic metastases.
Jeanett Klubien +5 more
doaj +1 more source
Surgical Case Reports, 2023 Background The rate of residual liver recurrence after the resection of colorectal liver metastases is high, and most cases recur within 5 years of the initial hepatectomy. Here, we report two cases of residual liver recurrence after radical resection of
Shotaro Yagi +11 more
doaj +1 more source
Current trends and outcomes of surgical treatment of colorectal cancer with liver metastasis
Сибирский онкологический журнал, 2022 Aim. To analyze multimodal treatment outcomes in patients with liver metastases from colorectal cancer, who were treated at multidisciplinary cancer clinic. Material and methods.
A. V. Shabunin +8 more
doaj +1 more source
Liver resection for non-colorectal, non-carcinoid, non-sarcoma metastases: a multicenter study. [PDF]
PLoS ONE, 2015 The role of liver resection for non-colorectal, non-neuroendocrine, non-sarcoma (NCNNNS) metastases is ill-defined. This study aimed to examine the oncologic outcomes of liver resection in such patients.A retrospective analysis of liver resection for ...
Guillaume Martel +6 more
doaj +1 more source